SEATTLE, WA / ACCESSWIRE / August 13, 2024 / MD Clarity, a leading provider of provider revenue optimization software, today announced its placement on the Inc. 5000 list of the fastest-growing private companies in America. This recognition highlights MD Clarity’s rapid growth and commitment to transforming the healthcare revenue cycle.
The Inc. 5000 list represents a comprehensive overview of the most innovative and successful independent businesses in the United States. Companies such as Microsoft, Dell, Pandora, LinkedIn, and Yelp gained their first national exposure as winners of the Inc. 5000.
MD Clarity’s inclusion in the Inc. 5000 reflects its impact improving revenue cycle outcomes, streamlining patients’ financial experience, and reducing the administrative burden on staff. By combining innovative technology with a deep understanding of healthcare, MD Clarity empowers providers to deliver exceptional patient care while optimizing their financial performance.
“We are thrilled to be recognized among the fastest growing companies in America,” said Dan Freeman, MD Clarity’s CEO. “This accomplishment is a testament to our team’s dedication to empowering Management Services Organizations (MSOs) and large physician-owned groups with our revenue optimization software. By addressing the complex financial challenges faced by these organizations, we’ve been able to drive significant growth while delivering exceptional results for providers and the patients they serve.”
About MD Clarity
MD Clarity is a powerful software platform transforming the revenue cycle of healthcare organizations. Through pre-service patient estimates and deposits, automated detection of variances between payer payments and contracted rates, and managed care agreement rate benchmarking and scenario modeling, MD Clarity enables the Revenue Cycle and Finance teams of healthcare organizations to boost cash flow. With a decade-long track record capturing the complexities of managed care agreements within its software platform, MD Clarity has grown to serve more than 150,000 providers. For more information, visit MDClarity.com or follow MD Clarity on LinkedIn.
Contact Information
David Freeman
Director of Strategy
david.freeman@mdclarity.com
SOURCE: MD Clarity
View the original press release on newswire.com.
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…
